Yissum - Research Development Company of the Hebrew University

In-Situ Generated Polymeric Devices for the Treatment of Aortic Abdominal Aneurysms (AAA)

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

An aneurysm is a localized dilation of a blood vessel that arises when a weakening and thinning section of an artery wall balloons out, and it represents a life-threatening pathology due to its potential for rupture
Project ID : 27-2006-374

Description of the technology

Highlights

The rupture of the aneurysmal sac, typically results in almost immediate death, with the burst ofAortic Abdominal Aneurysms (AAA) ranking as the 13th cause of mortality in the U.S.

The stent can be inserted with minimally invasive procedures:

  • Isolation of the weak aneurysmal arterial wall from the aortic blood stream, immediately minimizing the risk of life-threatening hemorrhage due to sudden rupture
  • Restoration of the artery's luminal cylindrical geometry, distorted by the aneurysmal expansion.

Innovation

The polymers used to make the stents and their properties and the method of expanding and sealing the polymer tube to the aorta.

Key Features

This minimally invasive surgical procedure protects an aortic aneurysm from rupture while restoring the aorta’s cylindrical geometry. It uses a thermo-expandable polymer tube (stent) that can be inserted into the aorta, and then subsequently expanded to allow the tube to tightly attach to the vessel, proximally and distally to the aneurysm so that it may isolate the aneurysmal arterial wall from the aortic blood stream. It has no interfaces that can cause endoleaks and provides a significantly lower cost alternative to typical endovascular aortic repair.

Development Milestones

Current Development Stage: Technology Readiness Level (TRL) = 6; i.e., System/subsystem model or prototype demonstrated in a relevant environment. Continued in vivo animal and human studies are needed to obtain regulatory approval unless substantial equivalence with approved devices can be shown.

The Opportunity

The formation of aneurysms is an extremely dangerous degenerative pathology of arterial tissues, especially common in adult and elderly populations, whereby the wall of the artery weakens locally and markedly expands. With an aging population in many nations, the market opportunity will only grow. This invention could cut healthcare costs while improving patient outcomes. The technology may also be useful for other analogous maladies.


Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Daniel Cohn
HUJI, Faculty of Science
The Institute of Chemistry

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.